Aptevo Announces Warrant Exercise Agreements Generating Approximately $3.0 Million
Aptevo Therapeutics said certain warrant holders agreed to cash exercises covering up to 2,777,778 shares, generating approximately $3.0 million in gross proceeds before fees and expenses.
Aptevo Therapeutics Inc. (NASDAQ:APVO) has announced warrant inducement agreements with certain holders of its existing common warrants. The arrangements provide for cash exercises covering up to 2,777,778 common shares at $1.08 per share and generated approximately $3.0 million in aggregate gross proceeds before placement agent fees and expenses.
Under the agreements, the participating holders committed to exercise their Existing Warrants in full for cash. In connection with those exercises, Aptevo will issue new, unregistered Inducement Warrants covering up to 13,888,890 common shares, also at an exercise price of $1.08 per share.
The new warrants will become exercisable on or after the date Aptevo obtains the required stockholder approval. They will expire five years after their initial exercise date.
Roth Capital Partners acted as Aptevo’s financial advisor. The company said the Inducement Warrants were offered through a private placement relying on an applicable exemption from the registration requirements of the Securities Act of 1933.
The common shares issuable through exercise of the Existing Warrants are covered by effective Form S-1 registration statements, including File No. 333-298483.
The Inducement Warrants and the shares issuable upon their exercise have not been registered under the Securities Act. They may not be offered or sold in the United States without registration with the Securities and Exchange Commission or an applicable exemption from registration requirements.
Aptevo has agreed to file a registration statement with the SEC covering the resale of common stock issuable upon exercise of the Inducement Warrants. The transaction carries further terms, restrictions and regulatory conditions not set out separately here.
Aptevo describes itself as a clinical-stage biotechnology company developing multispecific immuno-oncology therapeutics, including bispecific and trispecific immunotherapies for cancer. Its pipeline candidates are based on the ADAPTIR™ and ADAPTIR-FLEX™ platforms.
The company identifies mipletamig as its lead clinical candidate. It is being evaluated in RAINIER, a two-part Phase 1b/2 trial for frontline acute myeloid leukemia in combination with venetoclax and azacitidine. Mipletamig has received orphan drug designation for AML under the Orphan Drug Act.
Aptevo also describes work on APVO451, a targeted trispecific immunotherapy candidate for solid tumors, and a collaboration with Niowave covering up to three radiopharmaceutical oncology programmes. The company said the first programme is expected to target nectin-4 and that both preclinical molecules are expected to advance into investigational new drug-enabling studies in 2027.
Aptevo cautioned that forward-looking statements depend on its current intentions, beliefs and expectations and that actual results could differ materially. The risks it identified include deterioration in its business or prospects, difficulties obtaining or enforcing intellectual property protection, different results from later studies, adverse events, unexpected safety issues, constraints in radioisotope availability, manufacturing or supply, and changes in regulatory, social, macroeconomic and political conditions.
Aptevo announced agreements for cash exercises of Existing Warrants covering up to 2,777,778 common shares at $1.08 per share.
The transaction generated approximately $3.0 million in aggregate gross proceeds before placement agent fees and expenses.
Aptevo will issue unregistered Inducement Warrants covering up to 13,888,890 common shares at $1.08 per share.
The new warrants require the required stockholder approval before exercise and expire five years after their initial exercise date.
The Inducement Warrants and underlying shares remain subject to Securities Act registration or an applicable exemption, while Aptevo has agreed to file a resale registration statement with the SEC.
Aptevo Therapeutics announced that it had entered into warrant inducement letter agreements with certain holders of its existing common warrants. Under the agreements, the holders agreed to exercise their Existing Warrants in full for cash, and Aptevo agreed to issue new Inducement Warrants.
Aptevo Therapeutics said the transaction generated approximately $3.0 million in aggregate gross proceeds, before deducting placement agent fees and expenses.
The Existing Warrants cover the purchase of up to an aggregate of 2,777,778 Aptevo Therapeutics common shares. The holders agreed to exercise those warrants in full for cash at a reduced exercise price of $1.08 per share.
Aptevo Therapeutics will issue new, unregistered Inducement Warrants covering the purchase of up to an aggregate of 13,888,890 common shares. The Inducement Warrants have an exercise price of $1.08 per share.
The Inducement Warrants will be exercisable on or after the date Aptevo Therapeutics obtains the required stockholder approval. They will expire five years after their initial exercise date.
The shares issuable upon exercise of the Existing Warrants are registered under effective Form S-1 registration statements, including File No. 333-298483. The Inducement Warrants and the common shares issuable upon their exercise have not been registered under the Securities Act and cannot be offered or sold in the United States without registration with the SEC or an applicable exemption.
Aptevo Therapeutics has agreed to file a registration statement with the SEC covering the resale of common shares issuable upon exercise of the Inducement Warrants.
The source identifies Aptevo Therapeutics Inc. as trading on NASDAQ under the ticker symbol NASDAQ:APVO, and also identifies it as Nasdaq:APVO.
Aptevo Therapeutics is a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics. It focuses on bispecific and trispecific immunotherapies for cancer using its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platforms.
Aptevo Therapeutics' lead clinical candidate is mipletamig, which is being evaluated in RAINIER, a two-part Phase 1b/2 trial for frontline acute myeloid leukaemia in combination with standard-of-care venetoclax and azacitidine. Mipletamig has received orphan drug designation for AML under the Orphan Drug Act.
Aptevo Therapeutics said its solid-tumour work includes advancing APVO451, a targeted trispecific immunotherapy candidate, and a strategic collaboration with Niowave to develop up to three radiopharmaceutical oncology programmes. The first radiopharmaceutical programme is expected to target nectin-4, and the company said both preclinical molecules are expected to advance into investigational new drug-enabling studies in 2027.
Aptevo Therapeutics identifies risks including deterioration in its business or prospects, difficulties obtaining or enforcing intellectual property protection, different results from later studies, adverse events, unexpected safety issues, constraints in radioisotope availability, manufacturing or supply, and changes in regulatory, social, macroeconomic and political conditions. The company cautions that actual results could differ materially from its expectations and says it cannot guarantee that forward-looking statements will be accurate.